BioClinica Compass wins technology innovation award
NEWTOWN, PENNSYLVANIA, Sept. 30, 2014 – BioClinica, Inc., a leading provider of outsourced clinical trial services and eClinical Solutions, today announced that its Compass technology, a risk-based monitoring solution that improves overall quality in clinical trials, has won the inaugural Society for Clinical Data Management (SCDM) NextGen Technology Innovation (TIA) Award, presented as part of SCDM’s 2014 annual conference.
BioClinica’s entry utilizes “Intelligent Monitoring” to transform the way clinical trials are managed. Compass focuses on meaningful data, critical to the success of a trial, and makes it easy to view the overall performance of trial sites. Compass leverages intelligent monitoring to track trial performance and identify performance issues across sites and ensure the most efficient and effective use of resources.
The SCDM Award recognizes breakthrough innovations which use novel technologies or processes and provide real-life application for use in clinical trials. Compass, along with entrees from Maxisit and PHT, was chosen as a finalist from a broad field of entries. Courtney McBean, BioClinica’s Vice President of Clinical Innovation, presented Compass to an enthusiastic SCDM audience as part of the competition.
“On behalf of SCDM, I would like to congratulate BioClinica on winning our inaugural NextGen Technology Innovation Award and thank all of our participating companies for their entries,” said Derek Perrin, SCDM Vice-Chair. “Compass is exactly the kind of technology solution we want to highlight with this award. It is an innovative solution to meeting the newest challenge in clinical trials.”
“This award not only recognizes the value Compass brings to clinical research, it also represents the clinical trial community’s interest and willingness to embrace a new approach to monitoring,” said BioClinica CEO Mark Weinstein. “The FDA has made it clear – we should be focusing our attention on the data that matters most – and Compass is a valuable tool to help trial sponsors accomplish this objective.”
Courtney McBean will participate in a Risk-Based Monitoring panel at the upcoming Partnerships in Clinical Trials Europe conference in Barcelona, Spain. She will also be presenting a webinar to the clinical trial industry titled An Intelligent Approach to Risk-Based Monitoring - How People, Process and Tools can Improve Clinical Trial Quality on November 13th.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated clinical trial management technologies including eClinical solutions for clinical trial supply management, forecasting and optimization (CTSM), electronic data capture (EDC), randomization (IRT), and clinical trial management (CTMS). BioClinica and SYNARC merged in 2014 to create the world's foremost medical imaging and cardiovascular core lab with unrivalled scientific, regulatory and project management capabilities for advancing clinical trials. Together, our company offers our clients the industry's most comprehensive and diversified clinical imaging program with therapeutically aligned experts and increased operational scale. With 30 years of experience and over 4000 successful trials to date, BioClinica has supported the development of many new medicines through all phases of the clinical trial process. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on three continents, and supports worldwide eClinical, comprehensive cardiovascular safety, and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.